
Colonoscopy in 2010 revealed hyperplastic and adenomatous polyps of various sizes and three cancers in the remaining colon (Fig. 1).

The polyps were easily visualized; the cancers were all discovered in fixed folds from prior surgery making visualization very difficult. The histology of each cancer was different. Immunohistochemistry showed loss of MLH1 and PMS2 for all cancers, which confirmed that the patient had Lynch syndrome [2].

This patient developed six individual colon cancers over a 13-year period; five of the six cancers developed during surveillance. We propose two possible explanations for this: (i) the cancers grew unusually fast, or (ii) cancers or precursor lesions were missed during preceding colonoscopies [3, 4]. As the two cancers in 2001 were discovered after an interval of only 11 months since the previous colonoscopy, we believe that they were missed. It is likely that lesions were missed in 2005 as well, as all three cancers discovered in 2010 were located inside of or proximal to fixed folds related to previous surgeries, which made discovery difficult. In addition, it is highly improbable that this patient with two mutations associated with Lynch syndrome did not develop any polyps for 5 years, and then presented with the entire range of lesions in 2010, as he had done previously in 2001.

What can we learn from this case? First, Lynch syndrome should have been diagnosed in 2001. Second, the colonoscopy interval for this patient should have been 1–2 years, especially given the occurrence of two interval cancers in 2001 within 11 months of the previous colonoscopy. Finally, complete inspection with removal of all mucosa or polyps that appear abnormal is critical in the prevention of additional colorectal cancer in patients with a history of colorectal cancer and in particular with Lynch syndrome.

Fig. 1 Three cancers of the colon discovered in 2010. Top row: The initial endoscopic view of each cancer. Middle row: The best endoscopic view of each cancer. Bottom row: Histological appearance of each cancer (hematoxylin and eosin [H&E]). Pathological diagnosis and tumor grade [1] are shown below the images for each cancer.
Competing interests: None

J. Edakkanambeth Varayil1, T. C. Smyrk2, P. C. de Groen1
1 Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
2 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA

References

Bibliography
Endoscopy 2011; 43: E203–E204
© Georg Thieme Verlag KG Stuttgart · New York · ISSN 0013-726X

Corresponding author
P. C. de Groen, MD
Department of Medicine, Division of Gastroenterology and Hepatology, Mayo Clinic
200 First Street S.W. Rochester, MN 55905 USA
Fax: +1-507-284-0538